Phreesia (PHR) Beats Q2 Earnings Expectations

Phreesia (PHR) reported quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. Revenues totaled $117.26 million, exceeding expectations by 0.70%. The stock has gained 21% this year. Analysts are now focusing on the company’s future earnings outlook and estimate revisions.

Phreesia’s stock performance has outpaced the market in 2025, prompting investors to wonder about its next moves. Analysts suggest monitoring the company’s earnings outlook, as well as any changes in consensus estimates. The Zacks Rank system can assist in tracking these revisions and predicting future stock movements.

The industry outlook also plays a crucial role in stock performance. Phreesia belongs to the Medical Info Systems industry, currently ranked in the top 34% of Zacks industries. This ranking indicates potential for outperformance compared to lower-ranked industries. Investors are advised to stay updated on industry trends for informed investment decisions.

In the same industry, ImmunoPrecise Antibodies Ltd. (IPA) is expected to report a quarterly loss of $0.04 per share, with revenues projected at $4.13 million. Analysts are closely watching for any changes in estimates or performance indicators. This data will provide valuable insights for investors considering Phreesia and other industry stocks.